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The leucine-rich repeat kinase 2 (LRRK2) G2019S mutation is the most common genetic determinant of Parkinson disease
(PD) identiﬁed to date. It accounts for 1%–7% of PD in patients of European origin and 20%–40% in Ashkenazi Jews
and North African Arabs with PD. Previous studies concluded that patients from these populations all shared a common
Middle Eastern founder who lived in the 13th century. We tested this hypothesis by genotyping 25 microsatellite and
single-nucleotide–polymorphism markers in 22 families with G2019S and observed two distinct haplotypes. Haplotype
1 was present in 19 families of Ashkenazi Jewish and European ancestry, whereas haplotype 2 occurred in three European
American families. Using a maximum-likelihood method, we estimated that the families with haplotype 1 shared a
common ancestor 2,250 (95% conﬁdence interval 1,650–3,120) years ago, whereas those with haplotype 2 appeared to
share a more recent founder. Our data suggest two separate founding events for G2019S in these populations, beginning
at a time that coincides with the Jewish Diasporas.
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Parkinson disease (PD [MIM 168600]) is the second-most
common neurodegenerative disorder and is characterized
by bradykinesia, resting tremor, rigidity, and postural in-
stability.1,2 Although approximately one in ﬁve patients
with PD reports a family history of the disease, pedigrees
that demonstrate clear Mendelian inheritance are rare.3,4
Linkage analysis of extended pedigrees has implicated ﬁve
genes in autosomal recessive (PARK2 [MIM 600116 and
602544], PINK1 [MIM 605909], and PARK7 [MIM606324])
or dominant (SNCA [MIM 163890] and LRRK2 [MIM
609007]) parkinsonism that closely resembles PD.5–10How-
ever, with the exception of LRRK2,mutations in these genes
rarely result in typical late-onset PD. A single LRRK2 mu-
tation (G2019S) accounts for 0.7%–1.6% of sporadic and
2.8%–6.6% of familial PD cases of European origin.11–16
More-recent studies indicate a remarkably highprevalence
of G2019S in Ashkenazi Jews (13.3% sporadic; 29.7% fa-
milial) and North African Arabs (40.8% sporadic; 37.0%
familial) with PD.17,18 Patients heterozygous for G2019S
display clinical characteristics that are indistinguishable
from those of patients with PD in the general popula-
tion.11–18
Data from ﬁve studies of 90 unrelated G2019S-bear-
ing subjects of European or Middle Eastern–North African
(MENA) origin revealed that all shared the same haplo-
type, consistent with a common founder.11,16–19 The high
prevalence of the mutation in Ashkenazi Jews and North
African Arabs has led to the hypothesis that the mutation
originated in the Middle East.18 Lesage and colleagues19
used a likelihood-based haplotype approach20 in the study
of six families of North African or European origin car-
rying G2019S and estimated that these individuals shared
a common founder ∼725 years ago.19 Given the fact that
G2019S is widely distributed across Europe and occurs at
high frequency among Ashkenazi Jews and North African
Arabs, this relatively recent estimated date is difﬁcult to
reconcile with established patterns of humanmigration.21,22
Therefore, we collected genotype data on a larger sample
of subjects, to examine the hypotheses that (1) patients
with PD who are of European and MENA origin share a
single ancestral haplotype and (2) the most recent com-
mon ancestor lived in the 13th century.
The study population was derived from 1,611 unrelated
patients with PD and 1,647 control individuals enrolled
at seven movement-disorder clinics in three U.S. cities (Al-
bany, NY; Portland, OR; and Seattle). All patientsmet stan-
dardized diagnostic criteria for PD, as determined by a
movement-disorder specialist.23 Controls had no history
of parkinsonism, and most were spouses of patients with
PD. The institutional review boards at each participating
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site approved the study, and all subjects gave informed
consent. Among these subjects, we identiﬁed 21 patients
(1 homozygous, 20 heterozygous) and 1 control individual
with G2019S (19 of these subjects have been reported
elsewhere).12,24 For the present study, we included these
22 subjects, 23 of their family members (6 affected and
17 unaffected), and 30 unrelated G2019S-negative Euro-
pean American controls. Of the G2019S-positive families,
13 were of (non-Jewish) European origin, 3 deﬁned them-
selves as Ashkenazi Jews, and 6 were of unspeciﬁed Jewish
ancestry. However, the probands from those six families
all indicated that their ancestors emigrated from central/
eastern Europe or Russia and were thus likely descendants
of the Ashkenazim.
We systematically selected markers, to determine
whether our subjects carrying G2019S shared a common
haplotype, using data from an ongoing study in which we
are screening the entire LRRK2 coding region and ﬂanking
intronic sequence for new mutations. Complete sequence
data on all 51 exons were available for one subject homo-
zygous and for three subjects heterozygous for G2019S.
We compared these four individuals at 90 polymorphic
sites and found ﬁve (rs28903073, rs2404834, rs10784522,
rs10878405, and ss52051244) at which one subject
(IPD584) differed from one or more of the others (IPD289,
IPD452, and/or PD82801) at both alleles. We genotyped
these ﬁve SNPs, 18 markers included in previous stud-
ies,11,16,17,19,24 and two additional microsatellites (D12S331
and D12S1592) in all 75 subjects in our study population.
The markers (12 SNPs and 13 microsatellites) spanned 9
Mb across the PARK8 region. SNP genotyping was per-
formed by sequencing with the Applied Biosystems Big-
Dye Terminator v3.1 Cycle Sequencing Kit. Microsatellites
were ampliﬁed by PCR with use of ﬂuorescently labeled F
primers, were run on anABI PRISM3130Genetic Analyzer,
and were analyzed using GeneMapper 4.0 software (Ap-
plied Biosystems).
We estimated the age of the most recent common foun-
der using the program Estiage.20 Thismaximum-likelihood
method uses information on the recombination fractions
between the mutation and each marker, the frequencies
of the shared allele at each marker, and the position of
the ﬁrst marker in each direction that is no longer shared,
to calculate the number of generations (with 95% CI)
elapsed since the most recent common ancestor intro-
duced the mutation into the population. We deﬁned a
marker as shared among families if a single (best-call) allele
was included in all disease haplotypes or in at least half
and at signiﬁcantly greater frequency (Fisher’s exact test
) than in 60 inferred control haplotypes (collaps-ap .05
ing all other alleles into a single bin). Genetic-map posi-
tions for each marker were derived from the linkage-map-
ping server MAP-O-MAT, and physical positions were taken
from the National Center for Biotechnology Information
(NCBI) human genome assembly Build 35.25 Because many
of the markers used in the present study were tightly
linked, genetic distances between them could not be ac-
curately estimated from available genetic maps. Instead,
we used the genetic length and physical distance between
the extreme markers (D12S2080 and D12S1301) to cal-
culate an average of 0.30 cM per Mb across the entire
analyzed region and then computed recombination frac-
tions using the Kosambi mapping function.
In instances where marker phase could not be unambig-
uously resolved by pedigree data, we used PHASE v2.1.126
(Matthew Stephens’ Web site) to infer haplotypes. Since
the use of inferred haplotypes can introduce additional
uncertainty into age estimates, we ﬁrst divided PHASE calls
for each allele at a given marker into three categories by
probability: best ( ), plausible ( ), and un-P 1 .5 .05 ! P ! .5
likely ( ). We then performed four separate runs, inP ! .05
Estiage, to estimate the age of the most recent founder by
using haplotypes from only the families in which phase
could be unambiguously resolved across shared markers
or with the most likely (best call only), longest plausible,
or shortest plausible haplotypes inferred by PHASE (Mat-
thew Stephens’ Web site) in all families.
Two clearly distinct disease haplotypes (referred to here-
after as “haplotype 1” and “haplotype 2”) became evident
on inspection of the data (ﬁg. 1). Haplotype 1 included a
core region of 17 consecutive markers spanning 243 kb
(D12S2514 to D12S2519) that was shared by 19 families,
with the exception of one marker, D12S2515. Our group
and others have argued that D12S2515 is unstable and
that the allelic differences previously observed among dis-
ease haplotypes at this marker were likely due to recurrent
mutation rather than recombination.11,24 Data from the
current study further support this idea; all 19 families with
haplotype 1 shared alleles at three markers upstream from
D12S2515, including the A allele of rs28903073, which
was observed elsewhere in only 1 of 906 European Amer-
ican control chromosomes (ﬁg. 1).24 This suggests that the
A allele is identical by descent for haplotype 1 carriers and
that any discordant alleles at interveningmarkers (between
rs28903073 and G2019S) in these individuals arose via
new mutations. Thus, D12S2515 was excluded from the
data set used to reconstruct haplotypes and was not used
in subsequent common founder-age estimates. Haplotype
2 was present in three families of European descent (ﬁg. 1)
and could be differentiated from the core region of hap-
lotype 1 by ﬁve intragenic SNPs and one extragenic micro-
satellite (D12S2519). These included the two closest ﬂank-
ing markers, which were located 5 kb upstream (rs2404834)
and 6 kb downstream (rs10784522) from G2019S. Haplo-
type 2 extended a minimum of 6 Mb across the PARK8
region, from the 5′-most marker assayed (D12S2080) to
D12S1592. Haplotypes 1 and 2 appear to be rare in popu-
lations of European ancestry, since the frequency of hap-
lotype 1 can be no greater than that of the A allele at
rs28903073 (0.1%),24 and haplotype 2 was not observed in
our sample of 60 control chromosomes. Taken together,
these data strongly suggest that the disease chromosomes
in our study population originated from two separate
founders.
Figure 1. Comparison of G2019S-containing haplotypes across the LRRK2 region. Five intragenic markers (bold type) delineate two distinct haplotypes in which complete allele
sharing is indicated by blue (haplotype 1) or yellow (haplotype 2) shading. For haplotype 1, signiﬁcant but incomplete allele sharing is denoted by light-blue shading. For markers
for which phase could not be unambiguously determined, both alleles are shown with the best call, as inferred by PHASE (Matthew Stephens’ Web site) listed ﬁrst (alleles of
probability !.05 are in brackets). The proband of family IPD289 was homozygous for G2019S; thus, haplotypes for the paternal (p) and maternal (m) lineages are provided separately.
D12S2515 (shown in italics) is unstable and was not included in haplotype analyses.
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We then estimated the age of the most recent common
founder among the 19 families with haplotype 1, desig-
nating D12S2194 and D12S1048 as the boundaries of the
shared haplotype as determined by the aforementioned
criteria (table 1). Our ﬁrst approach, which was the one
most comparable to that used by Lesage and colleagues,19
restricted the analysis to families with phase-known data
within the shared region. This reduced the data set to ﬁve
families (IPD289, IPD452, PD82801, PN184, and PN196)
representing six disease chromosomes and produced an
age estimate of 65 (95% CI 36–121) generations. After in-
corporating the remaining 14 families forwhich phasewas
inferred, the best-call and longest haplotypes were iden-
tical and yielded an estimate of 75 (95% CI 55–104) gen-
erations, whereas the shortest haplotypes estimate was 84
(95% CI 61–117) generations. With use of the most widely
published intergenerational interval, 25 years,27 our best-
call data indicate that these families shared a common
ancestor 1,875 (95% CI 1,375–2,600) years ago. However,
several recent studies have concluded that 30 years is a
better approximation of generation time for the period of
human history in question.27–29 A 30-year intervalwithbest-
call haplotypes increases the age of the founding event to
2,250 (95%CI 1,650–3,120) years ago.We did not perform
age estimates for the three families with haplotype 2, be-
cause the sample size was small and we were not able to
deﬁne the 5′ limit of the shared region. However, since
the genetic length of the shared region is inversely pro-
portional to the age of the founding event, these three
families likely shared a common ancestor more recently
than did the haplotype 1 families.
Our study is the ﬁrst to provide evidence that G2019S-
positive patients of European ancestry originated from
more than one founder. In our sample, haplotypes 1 and
2 could be adequately distinguished only by inclusion of
ﬁve intragenic SNPs added on the basis of extensive se-
quence comparisons performed on a subset of probands.
Only one of these ﬁve SNPs (rs28903073) has been in-
cluded in similar analyses by other groups,11 so it is pos-
sible that both haplotypes were present among the 90
G2019S-bearing families of European or MENA origin re-
ported elsewhere.11,16–19 However, we suspect that the ma-
jority of these families will prove to carry haplotype 1, on
the basis of allele sharing at four extragenicmicrosatellites
(D12S2519, D12S2520, D12S2521, andD12S1048) assayed
in four of ﬁve studies11,16,17,19 and at rs28903073, which
was genotyped in a single study of 18 (largely Italian) fam-
ilies.11 This is consistent with our data and suggests that
haplotype 1 is predominant in European Americans and
Ashkenazi Jews—and likely inNorth AfricanArabs aswell—
carrying G2019S, which would be explained by a common
Middle Eastern founder. The geographic origin of haplo-
type 2 is less certain, but all three families in which it
occurred originated primarily from Western Europe.
Our age estimates for the most-recent common founder
for G2019S (haplotype 1) were two- to threefold larger
than the one calculated by Lesage and colleagues.19 There
were three potential differences of relevance between the
two studies: the physical distance shared among disease
chromosomes, our use of inferred haplotypes, and the es-
timation of recombination fraction between markers. We
observed a minimum shared region of 243 kb ﬂanking
G2019S in our sample, whereas Lesage et al.19 reported a
much shorter segment, 60 kb. We suspect that this was
due largely to their using an unstable marker (D12S2515)
to delineate the 5′ boundary of the shared segment and
possibly unknowingly combining subjects with haplotypes
1 and 2 in the analysis. Slight differences in the marker
sets genotyped in the two studies might also have had an
effect. However, this would not explain the difference in
age estimates, since our inclusion of longer disease hap-
lotypes would have the opposite effect (i.e., predict amore
recent ancestor). Likewise, our use of inferred haplotypes
in some families does not explain the discrepancy, be-
cause, even when the analysis was restricted to chromo-
somes of known phase, as was done in the study of Lesage
et al.,19 our estimate was still more than twice as large (65
vs. 29 generations). Furthermore, our inclusion of recon-
structed haplotypes in 14 of 19 families allowed more-
efﬁcient use of the data set, with minimal added uncer-
tainty in the estimate, as evidenced by the narrow range
of ages calculated using the longest or shortest plausible
haplotypes (75 vs. 84 generations). The only remaining
explanation to account for the discrepancy between the
two studies is that we must have used lower recombina-
tion fractions in themaximum-likelihood calculations (ta-
ble 1). Lower recombination fractions correspond to a de-
creased genetic length of the segment shared among dis-
ease chromosomes and an increased estimated time since
the last common ancestor. This general relationship is ap-
parent when our estimate of 75 generations, based on a
shared segment of !0.2 cM, is comparedwith two previous
studies that used Estiage to estimate a founder age of 46
generations (0.7–12.6 cM shared) for the AAAS (MIM
605378) IVS141GrAmutation and 23 generations (7 cM
shared) for the VAPB P56S mutation (MIM 605704 and
608627).20,30 In contrast, Lesage and colleagues19 calcu-
lated an age of only 29 generations, using a shared phys-
ical distance less than what we used.We cannot determine
the degree to which our estimated recombination frac-
tions differed from theirs, because they have not pub-
lished these data, although the genetic distances used in
both studies were derived from the same source (MAP-O-
MAT).
Our data are consistent with the hypothesis of Ozelius
and colleagues18 that Europeans, Ashkenazi Jews, andNorth
African Arabs with G2019S arose from a common Middle
Eastern founder, if only those individuals with haplotype
1 are considered. Our best estimate suggests that the com-
mon ancestor lived 2,250 years ago, during the period of
the Jewish Diasporas (586 BC to 70 AD), at a time when
the ancestral Jewish population and some Arab commu-
nities existed in close proximity. Similar age estimates have
been calculated for other disease alleles found at high fre-
Table 1. Data Used in Estimating the Age of the G2019S Haplotype 1 Common Founder
Marker
Data Used for Family
Distanceb vc FrequencydIPD289(p)a IPD289(m)a IPD483 PN65 PN371 PN196 FP0079 FP0341 IPD452 FP0353 PN718 PD82801 PN278 IPD374 PN961 IPD197 FP0021 PN184 PN5664 IPD620
D12S331 181 181 181 181 181 181 181 181 181 181 181 177 177 177 177 179 1.473 .0045
D12S2194 257 257 257 257 257 257 257 257 257 257 257 257 257 257 257 257 261 261 261 253 .282 .0009 .20
D12S2514 291 291 291 291 291 291 291 291 291 291 291 291 291 291 291 291 291 291 291 291 .147 .0004 .53
rs10878245 C C C C C C C C C C C C C C C C C C C C .102 .0003 .60
rs28903073 A A A A A A A A A A A A A A A A A A A A .081 .0002 .001
rs7966550 T T T T T T T T T T T T T T T T T T T T .046 .0001 .85
D12S2516 254 254 254 254 254 254 254 254 254 254 254 254 254 254 254 254 254 254 254 254 .031 .00009 .63
rs1896252 C C C C C C C C C C C C C C C C C C C C .020 .00006 .62
rs1427263 A A A A A A A A A A A A A A A A A A A A .020 .00006 .68
rs11176013 G G G G G G G G G G G G G G G G G G G G .020 .00006 .62
rs11564148 A A A A A A A A A A A A A A A A A A A A .020 .00006 .39
rs2404834 C C C C C C C C C C C C C C C C C C C C .005 .00002 .91
G2019S A A A A A A A A A A A A A A A A A A A A 0 0
rs10784522 T T T T T T T T T T T T T T T T T T T T .006 .00002 .40
rs10878405 A A A A A A A A A A A A A A A A A A A A .008 .00002 .40
D12S2518 154 154 154 154 154 154 154 154 154 154 154 154 154 154 154 154 154 154 154 154 .014 .00004 .80
ss52051244 A A A A A A A A A A A A A A A A A A A A .023 .00007 .88
rs3761863 C C C C C C C C C C C C C C C C C C C C .024 .00007 .67
D12S2519 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 132 .096 .0003 .30
D12S2520 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 260 257 260 .100 .0003 .20
D12S2521 359 359 359 359 359 359 359 359 359 359 359 359 359 359 359 359 359 355 359 .108 .0003 .08
D12S1048 214 214 214 214 214 214 214 214 214 214 214 214 214 214 214 214 214 211 .292 .0009 .21
D12S1592 254 256 256 256 254 254 256 254 256 254 256 254 254 254 254 254 254 1.711 .0052
NOTE.—The interval between markers D12S2194 and D12S1048 was deﬁned as shared and, within this segment phase, was inferred for 14 of 20 disease chromosomes. Marker D12S2515 is unstable and was excluded from the analysis.
a The proband of family IPD289 was homozygous for G2019S; thus, haplotypes from the paternal (p) and maternal (m) lineages are provided separately.
b Physical distance (Mb) between G2019S and each marker, from NCBI Build 35.
c Recombination fraction between G2019S and each marker, calculated using the Kosambi mapping function and an average of 0.30 cM per Mb across the entire region.
d Frequencies of the shared allele were taken from Kachergus et al.16 for microsatellites and 30 International HapMap Project CEPH trios for SNP markers, except for rs28903073 (which was from a previous report24) and ss52051244
(which was derived from 60 European American control chromosomes genotyped in this study).
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quency among Ashkenazi Jews, non-Ashkenazi Jews, and
Arabs, including the factor XI deﬁciency type II F11 (MIM
264900) E117X mutation and the APC (MIM 175100)
I1307K variant, which increases risk for colorectal can-
cer.22,31 Thus, Lesage and colleagues’ conclusion that the
G2019S founding event occurred in the 13th century19
appears implausible, since, by that time, Jews destined to
become Ashkenazim had been separated from Arab and
other Jewish communities for many centuries.
Our data provide an important framework for further
investigation of the widespread expansion of G2019S over
the past two millennia. Mapping the frequency of disease
haplotypes 1 and 2 in European and MENA populations,
with use of the marker set described above, will be critical
in this endeavor, particularly in non–Ashkenazi Jewish
and non-Jewish communities in theMiddle East. Deﬁning
the age and origin of haplotype 2 might help to explain
the variable prevalence of the mutation across Europe.
Finally, G2019S was recently identiﬁed in an Asian pop-
ulation24 on a haplotype background clearly distinct from
the two observed here, which indicates that at least three
founding events have occurred. It is becoming clear that
the genetic and demographic processes that have shaped
the current distribution of G2019S across the world are
more complex than previously recognized.
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